James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Yahoo! Inc. (YHOO) CEO Marissa Mayer’s Final Humiliation?

Just when owners of Yahoo stock though the debacle was over, another batch of Mayer's bad decisions hit YHOO at the worst possible time.

Why Mylan NV (MYL), Tesla Motors Inc (TSLA) and Twitter Inc (TWTR) Are 3 of Today’s Worst Stocks

Mylan (MYL), Tesla Motors (TSLA) and Twitter (TWTR) shareholders couldn't get rid of their positions fast enough on Thursday.

Why EVERY Twitter Stock Holder Should’ve Known Better

Twitter stock is down 16% following reports that most of the presumed buyers were bowing out ... if they were ever truly interested in TWTR in the first place.

Apple Inc. (AAPL) Stock Has Zero Need for Netflix, Inc. (NFLX)

Apple (AAPL) stock has been tough to own for over a year now, but getting in bed with Netflix (NFLX) isn't apt to help on that front.

Why Salesforce.com, Inc. (CRM), Immunomedics, Inc. (IMMU) and Verizon Communications Inc. (VZ) Are 3 of Today’s Worst Stocks

Immunomedics (IMMU), Verizon Communications (VZ) and Salesforce (CRM) couldn't win for losing on Wednesday.